Compare Inovio Pharmaceuticals Inc (INO) vs iShares Core S&P 500 ETF (IVV) Price & Performance

Inovio Pharmaceuticals IncTrade

iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs iShares Core S&P 500 ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while iShares Core S&P 500 ETF trades at $749.75. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

	INO	IVV
Market Cap	$89.27M	—
Sector	Health	Broad Market / Factor
52-Week High	$2.87	$763.10
52-Week Low	$1.05	$624.65
Enterprise Value	$60.28M	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $745.67, down 0.14% with a bearish technical signal from moving averages. The fund remains heavily weighted toward technology stocks, with recent news highlighting concentration risks and debates over valuation. A dividend of $2.00 is scheduled for June 2026, providing income amid market volatility.

Outlook is cautious due to technical weakness and high tech exposure, though long-term growth prospects from AI and earnings strength offer potential. Key risks include market concentration, valuation concerns, and macroeconomic shifts impacting broad index performance.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INO

View details →

IVV

Invesco S&P 500 Equal Weight Consumer Discretionary ETF seen as a Hold, likely underperforming IVV again.Seeking Alpha · 2 days agoNeutral BlackRock's MAXJ ETF offers S&P 500 returns with downside protection but caps gains at 10.6%.24/7 Wall Street · 3 days agoNeutral SPY ETF charges higher fees than its cheaper sibling SPYM with identical S&P 500 exposure.24/7 Wall Street · 3 days agoBearish View details →

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.